InTERTesting association between telomerase, mTOR and phytochemicals

Tabetha Sundin1, Patricia Hentosh

  • 1Department of Biological Sciences, Old Dominion University, Norfolk, VA 23529, USA.

Insights

Phytochemicals inhibit telomerase, an enzyme crucial for cancer cell immortality. This review explores how mTOR signaling and phytochemicals regulate telomerase activity, offering potential therapeutic strategies against cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Telomeres protect chromosome ends from degradation during DNA replication.
  • Telomerase, active in ~90% of human cancers, enables cancer cell immortality by adding telomeric repeats.
  • Phytochemicals like resveratrol and curcumin are known to inhibit telomerase activity.

Purpose of the Study:

  • To elucidate the role of mammalian target of rapamycin (mTOR) in regulating telomerase activity.
  • To review the mechanisms by which phytochemicals inhibit telomerase.
  • To explore the interplay between mTOR signaling, telomerase, and phytochemicals in cancer.

Main Methods:

  • Review of existing literature on telomere biology, telomerase regulation, and phytochemical effects.
  • Analysis of the physical and functional complex involving human TERT, HSP90, Akt, S6K, and mTOR.
  • Examination of mTOR's role as a master regulator of protein translation in telomerase control.

Main Results:

  • The mammalian target of rapamycin (mTOR) pathway is integral to telomerase regulation, forming a complex with telomerase reverse transcriptase (TERT) and other key proteins.
  • Phytochemicals exert inhibitory effects on telomerase through various mechanisms.
  • Akt, S6K, and mTOR are components of the TERT complex, indicating mTOR-mediated control of telomerase.

Conclusions:

  • mTOR signaling is a critical regulator of telomerase activity, influencing cancer cell proliferation and survival.
  • Phytochemicals represent a promising class of compounds for targeting telomerase in cancer therapy.
  • Understanding the intricate regulation of telomerase by mTOR and phytochemicals can lead to novel anti-cancer strategies.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Telomeres and Telomerase02:41

Telomeres and Telomerase

In eukaryotic DNA replication, a single-stranded DNA fragment remains at the end of a chromosome after the removal of the final primer. This section of DNA cannot be replicated in the same manner as the rest of the strand because there is no 3’ end to which the newly synthesized DNA can attach. This non-replicated fragment results in gradual loss of the chromosomal DNA during each cell duplication. Additionally, it can induce a DNA damage response by enzymes that recognize single-stranded DNA.
Telomeres and Telomerase02:41

Telomeres and Telomerase

In eukaryotic DNA replication, a single-stranded DNA fragment remains at the end of a chromosome after the removal of the final primer. This section of DNA cannot be replicated in the same manner as the rest of the strand because there is no 3’ end to which the newly synthesized DNA can attach. This non-replicated fragment results in gradual loss of the chromosomal DNA during each cell duplication. Additionally, it can induce a DNA damage response by enzymes that recognize single-stranded DNA.
Replicative Cell Senescence02:15

Replicative Cell Senescence

Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds the telomeric...